Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II Randomized, Double-blind, Placebo-controlled Trial of MCMV5322A/MCMV3068A for the Prevention of Cytomegalovirus Disease in High-risk Kidney Allograft Recipients

Next Previous
Trial Profile

A Phase II Randomized, Double-blind, Placebo-controlled Trial of MCMV5322A/MCMV3068A for the Prevention of Cytomegalovirus Disease in High-risk Kidney Allograft Recipients

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 25 Jul 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs RG 7667 (Primary)
  • Indications Cytomegalovirus infections
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Genentech

Most Recent Events

  • 13 Nov 2017 Results assessing the safety and pharmacological activity of multiple doses of RG7667 in preventing CMV infection in kidney transplant recipients, were published in the Antimicrobial Agents and Chemotherapy.
  • 12 Nov 2016 Primary endpoint (Percentage of Participants With CMV Viral Load Greater than or Equal to 150 Copies per Milliliter (Copies/mL) During the First 12 Weeks After Transplantation) has not been met,according to the results published in the Antimicrobial Agents and Chemotherapy.
  • 12 Nov 2016 Results published in the Antimicrobial Agents and Chemotherapy

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top